These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 34131221)

  • 1. Pharmacological and clinical evaluation of deferasirox formulations for treatment tailoring.
    Piolatto A; Berchialla P; Allegra S; De Francia S; Ferrero GB; Piga A; Longo F
    Sci Rep; 2021 Jun; 11(1):12581. PubMed ID: 34131221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adherence to iron chelation therapy in patients who switched from deferasirox dispersible tablets to deferasirox film-coated tablets.
    Cheng WY; Said Q; Hao Y; Xiao Y; Vekeman F; Bobbili P; Duh MS; Nandal S; Blinder M
    Curr Med Res Opin; 2018 Nov; 34(11):1959-1966. PubMed ID: 29701080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adherence to Iron Chelation Therapy with Deferasirox Formulations among Patients with Sickle Cell Disease and β-thalassemia.
    Oyedeji CI; Crawford RD; Shah N
    J Natl Med Assoc; 2021 Apr; 113(2):170-176. PubMed ID: 32892996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Compliance and clinical benefit of deferasirox granule and dispersible tablet formulation in pediatric patients with transfusional iron overload: in a randomized, open-label, multicenter, phase II study.
    Taher AT; Wali Y; Cruz MC; Charoenkwan P; Aydinok Y; Werner O; Govindaraju S; Romen F; Viprakasit V
    Haematologica; 2024 May; 109(5):1413-1425. PubMed ID: 37855069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-reported outcomes from a randomized phase II study of the deferasirox film-coated tablet in patients with transfusion-dependent anemias.
    Taher AT; Origa R; Perrotta S; Kouraklis A; Ruffo GB; Kattamis A; Goh AS; Huang V; Zia A; Herranz RM; Porter JB
    Health Qual Life Outcomes; 2018 Nov; 16(1):216. PubMed ID: 30453981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient preference for deferasirox film-coated versus dispersible tablet formulation: a sequential-design phase 2 study in patients with thalassemia.
    Viprakasit V; Hamdy MM; Hassab HMA; Sherief LM; Al-Bagshi M; Khattab M; Chuncharunee S; Dung PC; Küpesiz A; Shekhawat A; Sonawane Y; Perez LT; Slader C; Taher AT
    Ann Hematol; 2023 Aug; 102(8):2039-2049. PubMed ID: 37227493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of deferasirox for reducing total body and cardiac iron in thalassemia.
    Merchant R; Ahmed J; Krishnan P; Jankharia B
    Indian Pediatr; 2012 Apr; 49(4):281-5. PubMed ID: 21992861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated total iron-binding capacity as a predictor of response to deferasirox therapy in the setting of chronic iron overload.
    Watanabe J; Sato K; Horiuchi T; Kato S; Hikota R; Maekawa T; Yamamura T; Kobayashi A; Osawa Y; Kobayashi S; Kimura F
    Int J Hematol; 2014 Sep; 100(3):254-9. PubMed ID: 24986748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias.
    Cappellini MD; Porter J; El-Beshlawy A; Li CK; Seymour JF; Elalfy M; Gattermann N; Giraudier S; Lee JW; Chan LL; Lin KH; Rose C; Taher A; Thein SL; Viprakasit V; Habr D; Domokos G; Roubert B; Kattamis A;
    Haematologica; 2010 Apr; 95(4):557-66. PubMed ID: 19951979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial.
    Maggio A; Kattamis A; Felisi M; Reggiardo G; El-Beshlawy A; Bejaoui M; Sherief L; Christou S; Cosmi C; Della Pasqua O; Del Vecchio GC; Filosa A; Cuccia L; Hassab H; Kreka M; Origa R; Putti MC; Spino M; Telfer P; Tempesta B; Vitrano A; Tsang YC; Zaka A; Tricta F; Bonifazi D; Ceci A
    Lancet Haematol; 2020 Jun; 7(6):e469-e478. PubMed ID: 32470438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of deferasirox estimated by serum ferritin and labile plasma iron levels in patients with aplastic anemia, myelodysplastic syndrome, or acute myeloid leukemia with transfusional iron overload.
    Kim IH; Moon JH; Lim SN; Sohn SK; Kim HG; Lee GW; Kim YS; Lee HS; Kwon KY; Kim SH; Park KT; Chung JS; Lee WS; Lee SM; Hyun MS; Kim H; Ryoo HM; Bae SH; Joo YD
    Transfusion; 2015 Jul; 55(7):1613-20. PubMed ID: 25764017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic mechanism of combined oral chelation therapy to maximize efficacy of iron removal in transfusion-dependent thalassemia major - a pilot study.
    Lin CH; Chen X; Wu CC; Wu KH; Song TS; Weng TF; Hsieh YW; Peng CT
    Expert Rev Hematol; 2019 Apr; 12(4):265-272. PubMed ID: 30920854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and Safety of Deferasirox in Thalassemia with Iron Overload: A Meta-Analysis.
    Dou H; Qin Y; Chen G; Zhao Y
    Acta Haematol; 2019; 141(1):32-42. PubMed ID: 30504715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower-risk MDS: Results of the randomized, phase II ECLIPSE study.
    Taher AT; Origa R; Perrotta S; Kourakli A; Ruffo GB; Kattamis A; Goh AS; Cortoos A; Huang V; Weill M; Merino Herranz R; Porter JB
    Am J Hematol; 2017 May; 92(5):420-428. PubMed ID: 28142202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimising management of deferasirox therapy for patients with transfusion-dependent thalassaemia and lower-risk myelodysplastic syndromes.
    Kattamis A; Aydinok Y; Taher A
    Eur J Haematol; 2018 Sep; 101(3):272-282. PubMed ID: 29904950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deferasirox in the treatment of iron overload during myeloproliferative neoplasms in fibrotic phase: does ferritin decrement matter?
    Di Veroli A; Campagna A; De Muro M; Maurillo L; Trawinska MM; LeonettiCrescenzi S; Petriccione L; Romano A; D'Addosio A; Cenfra A; Montanaro M; Felici S; Andriani A; Carmosino I; Niscola P; Montefusco E; Breccia M; Latagliata R
    Leuk Res; 2019 Jan; 76():65-69. PubMed ID: 30578958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deferasirox in children with transfusion-dependent thalassemia or sickle cell anemia: A large cohort real-life experience from Turkey (REACH-THEM).
    Antmen B; Karakaş Z; Yeşilipek MA; Küpesiz OA; Şaşmaz İ; Uygun V; Kurtoğlu E; Oktay G; Aydogan G; Akın M; Salcioglu Z; Vergin C; Kazancı EG; Ünal S; Çalışkan Ü; Aral YZ; Türkkan E; Meral Güneş A; Tunç B; Gümrük F; Ayhan AC; Söker M; Koç A; Oymak Y; Ertem M; Timur Ç; Yıldırmak Y; İrken G; Apak H; Biner B; Eren TG; Işık Balcı Y; Koçak Ü; Karasu G; Akkaynak D; Patıroğlu T
    Eur J Haematol; 2019 Feb; 102(2):123-130. PubMed ID: 30300449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term effects of an oral iron chelator, deferasirox, in hemodialysis patients with iron overload.
    Chen CH; Shu KH; Yang Y
    Hematology; 2015 Jun; 20(5):304-10. PubMed ID: 25200910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
    Nolte F; Höchsmann B; Giagounidis A; Lübbert M; Platzbecker U; Haase D; Lück A; Gattermann N; Taupitz M; Baier M; Leismann O; Junkes A; Schumann C; Hofmann WK; Schrezenmeier H
    Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deferasirox chelation therapy in patients with transfusion-dependent MDS: a 'real-world' report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata.
    Maurillo L; Breccia M; Buccisano F; Voso MT; Niscola P; Trapè G; Tatarelli C; D'Addosio A; Latagliata R; Fenu S; Piccioni AL; Fragasso A; Aloe Spiriti MA; Refrigeri M; Criscuolo M; Musto P; Venditti A
    Eur J Haematol; 2015 Jul; 95(1):52-6. PubMed ID: 25764148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.